| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-08-16 | Krystal Biotech (USA - PA) | $10 million | private placement | Frazier Healthcare Partners (USA - WA) | Rare diseases - Genetic diseases | Private placement |
| 2018-08-13 | Orchard Therapeutics (UK) | $150 Million | series C financing round | ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA) | Rare diseases - Genetic diseases | Series C financing round |
| 2018-08-08 | Beigene (China) | $903 million | IPO | Cancer - Oncology | IPO | |
| 2018-08-06 | Pharmaxis (Australia) | A$24 million (£13.4 million - €15.35 million) | financing round | Arix Bioscience (UK) BVF Partners (USA - CA) other existing shareholders | Fibrotic diseases - Inflammatory diseases | Financing round |
| 2018-08-03 | Drug Discovery Gateway Investment Limited Partnership - DDG Fund (Japan) | financing round | Takeda Pharmaceutical (Japan) Whiz Partners (Japan) | Financing round | ||
| 2018-07-31 | AC Immune (Switzerland) | $117.5 million | private placement | Neurological diseases - CNS diseases | Private placement | |
| 2018-07-28 | Bluebird Bio (USA - MA) | $550 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-07-23 | Azafaros (The Netherlands) | seed financing round | BioGeneration Ventures (The Netherlands) | Rare diseases - Genetic diseases - Metabolic diseases | Financing round | |
| 2018-07-23 | OliX Pharmaceuticals (South Korea) | KRW43 billion ($38 million) | IPO | Fibrotic diseases - Ophtalmological diseases | IPO | |
| 2018-07-06 | Oncologie (USA - MA - China) | $16.5 million | seed financing round | Nan Fung Life Sciences (China) Pivotal bioVenture Partners China Fund (China) China Merchant Bank Investments (China) Volcanics Ventures (China) | Cancer - Oncology | Financing round |
| 2018-06-28 | Innovation Pharmaceuticals (USA - MA) | $7 million | private placement | Aspire Capital (USA - IL) | Cancer - Oncology - Infectious diseases | Private placement |
| 2018-06-25 | Avrobio (USA - MA) | $114.7 million | IPO | Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases | IPO | |
| 2018-06-25 | Akero Therapeutics (USA - MA) | $65 Million | series A financing round | Apple Tree Partners (USA - NY) Atlas Venture (USA - MA) venBio Partners (USA - CA) Versant Ventures (USA - CA) | Liver diseases - Hepatic diseases | Series A financing round |
| 2018-06-12 | MeiraGTx (USA - NY) | $75 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-05-30 | Iontas (UK) | £556 000 ($737 000) | grant | Innovate UK (UK) | CNS diseases | Grant |
| 2018-05-29 | Melinta Therapeutics (USA - CT) | private placement | Infectious diseases | Private placement | ||
| 2018-05-29 | Mereo BioPharma (UK) | private placement | Rare diseases | Private placement | ||
| 2018-05-23 | Celyad (Belgium) | $54.4 million (approximately €46.1 million), | private placement | Cancer - Oncology | Private placement | |
| 2018-05-16 | HiFiBiO Therapeutics (USA - MA) | $37.5 million | series B financing round | Sequoia China (China) LYFE Capital (China) VI Ventures (China) Nest.Bio Ventures (USA - MA) Legend Star Capital (China) Proxima Ventures (Israel) | Technology - Services | Series B financing round |
| 2018-05-09 | IGEM Therapeutics (UK) | £1.45 million | grant | Innovate UK (UK) | Cancer - Oncology | Grant |
